RxDoctor Payments Data

Abdur Khan, MD

Interventional Cardiology · Boston, MANPI 1700132750

Payments from drug & device makers

$6,930in general payments, 2019–2025

Across 72 payments — averaging $96.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Siemens Medical Solutions USA, Inc.$2K
  • Bard Peripheral Vascular, Inc.$2K
  • Abbott$194
  • Novartis$160
  • Philips North America LLC$140
  • plus $529 from 16 others

What the payments were for

  • Travel & lodging$4,62167%
  • Food & beverage$2,14431%
  • Education$1652%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,930 in reported general payments places this provider in the 50th percentile of 128 interventional cardiology providers in Massachusetts.

See all interventional cardiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$138,906
Medicare patients
867
Services billed
1,961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban162$186,756
XareltoRivaroxaban30$35,379
FarxigaDapagliflozin Propanediol21$27,309
BrilintaTicagrelor16$20,528
EntrestoSacubitril/Valsartan13$19,413
Atorvastatin Calcium507$6,417
Praluent PenAlirocumab12$5,708
Metoprolol Succinate345$5,114
Ranolazine ErRanolazine39$4,713
ClopidogrelClopidogrel Bisulfate294$3,759
Isosorbide Mononitrate ErIsosorbide Mononitrate157$2,294
Amlodipine Besylate190$1,583
Losartan Potassium158$1,570
Lisinopril174$1,508
Carvedilol137$1,140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$186,756162 claims
AstraZenecaFarxiga, Brilinta$15$47,83737 claims
NovartisEntresto$160$19,41313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 128 interventional cardiology providers in Massachusetts.

Other interventional cardiology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →